Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| O-Tolylamine SCHEMBL19586028 | 0.91 | NPC1 (0.49) | NPC1RAB9AHPGDALDH1A1PDK1 | |
| SCHEMBL2880191 | 0.89 | LMNA (0.54) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL4414634 | 0.87 | LMNA (0.48) | NPC1RAB9AHPGDALDH1A1PDK1 | |
| SCHEMBL2880194 | 0.86 | BRD9 (0.52) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL8348015 | 0.84 | PDK1 (0.52) | NPC1RAB9AHPGDALDH1A1PDK1 | |
| SCHEMBL1006923 | 0.83 | LCK (0.45) | NPC1RAB9APOLBBRD9LMNA | |
| SCHEMBL29493510 | 0.83 | LCK (0.45) | NPC1RAB9APOLBBRD9LMNA | |
| SCHEMBL28856066 | 0.83 | RXFP1 (0.47) | NPC1RAB9APDK1PDK2PDK3 | |
| SCHEMBL21681358 | 0.83 | LCK (0.46) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL9685813 | 0.83 | LCK (0.45) | NPC1RAB9AHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025010394-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF INFLAMMATORY CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025010392-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4457213-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | Psy Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118574807-A | Inhibition of monoacylglycerol lipase (MAGL) | PSY治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0914125-A4 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO INC (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5968924-A | HAVE THE ABILITY TO STIMULATE THE RELEASE OF NATURAL OR ENDOGENOUS GROWTH HORMONE; TREATMENT OF OBESITY, OSTEOPOROSIS | MERCK & CO., INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0914125-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | Merck & Co., Inc. (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5846978-A | HIV protease inhibitors useful for the treatment of AIDS | MERCK & CO., INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997040833-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1997-11-06 | — | — | WO | disclosed |
| EP-0082523-B1 | INTERMEDIATES FOR THE PREPARATION OF 4-PHENYL-1,3-BENZODIAZEPINS AND METHODS FOR PREPARING THE INTERMEDIATES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-04-02 | — | — | EP | disclosed |
| US-4461728-A | Preparation of 4-phenyl-1,3-benzodiazepins | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1984-07-24 | — | — | US | disclosed |
| EP-0082523-A2 | Intermediates for the preparation of 4-phenyl-1,3-benzodiazepins and methods for preparing the intermediates | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-29 | — | — | EP | disclosed |
| US-4374067-A | Intermediates for the preparation of 4-phenyl-1,3-benzodiazepins and methods for preparing the intermediates | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1983-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | NPC1 334/4885RAB9A 1093/4885HPGD 2668/4885 |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LPL | NPC1 300/4885RAB9A 2094/4885HPGD 835/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | NPC1 334/4885RAB9A 1093/4885HPGD 2668/4885 |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | NPC1 982/4885RAB9A 1440/4885HPGD 670/4885 |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | NPC1 563/4885RAB9A 1248/4885HPGD 1662/4885 |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | NPC1 334/4885RAB9A 1093/4885HPGD 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.